Table 1. Patient characteristics.
| Characteristic | Overall population | Stage I+II (n=134) | Stage III (n=120) | p-value |
|---|---|---|---|---|
| Age (yr) | 0.07 | |||
| ≤65 | 154 (60.6) | 75 (56.0) | 79 (65.8) | |
| >65 | 100 (39.4) | 59 (44.0) | 41 (34.2) | |
| Lymphadenectomy | <0.001 | |||
| No | 89 (35.0) | 61 (45.5) | 28 (23.3) | |
| Pelvic | 137 (54.0) | 67 (50.0) | 70 (58.3) | |
| Pelvic+aortic | 28 (11.0) | 6 (4.5) | 22 (18.3) | |
| Stage | ||||
| IB | 61 (24.0) | |||
| II | 73 (28.7) | |||
| IIIA | 54 (21.3) | |||
| IIIB | 8 (3.2) | |||
| IIIC | 58 (22.8) | |||
| Myometrial invasion (%) | 0.001 | |||
| No | 0 | 0 | 0 | |
| ≤50 | 73 (28.7) | 27 (20.2) | 46 (38.3) | |
| >50 | 181 (71.3) | 107 (79.9) | 74 (61.7) | |
| Grade | 0.001 | |||
| 1 | 15 (5.9) | 5 (3.7) | 10 (8.3) | |
| 2 | 104 (40.9) | 43 (32.1) | 61 (50.8) | |
| 3 | 135 (53.2) | 86 (64.2) | 49 (40.8) | |
| LVSI | 0.049 | |||
| Negative | 166 (65.9) | 95 (70.9) | 71 (60.2) | |
| Positive | 86 (34.1) | 39 (29.1) | 47 (39.8) | |
| Peritoneal | ||||
| Cytology NA | 20 | 15 | 5 | |
| Negative | 203 | 119 | 84 | |
| Positive | 31 | 7 | 24 | |
| Adjuvant therapy | <0.001 | |||
| No | 55 (21.7) | 48 (35.8) | 7 (5.8) | |
| EBRT | 98 (38.6) | 60 (44.8) | 38 (31.7) | |
| Chemo | 59 (23.2) | 13 (9.7) | 46 (38.3) | |
| Sequential | 42 (16.5) | 13 (9.7) | 29 (24.2) | |
| Chemo-EBRT |
Values are presented as number (%).
EBRT, external beam radiotherapy; LVSI, lymphovascular space involvement, NA, not available.